
  
    
      
        Background_NNP
        Medulloblastomas_NNP ,_, embryonal_NN neoplasms_NNS arising_VBG in_IN the_DT
        cerebellum_NN ,_, are_VBP the_DT most_RBS common_JJ malignant_JJ pediatric_JJ brain_NN
        tumor_NN ._. In_IN man_NN ,_, three_CD inherited_VBN syndromes_NNS associated_VBN with_IN
        medulloblastomas_NNS have_VBP been_VBN described_VBN :_: Turcot_NNP 's_POS ,_, Gorlin_NNP 's_POS
        and_CC Li_NNP Fraumeni_NNP (_( reviewed_VBN in_IN [_NN 1_CD ]_NN )_) ._. Li_NNP Fraumeni_NNP syndrome_NN
        is_VBZ caused_VBN by_IN inherited_VBN mutations_NNS in_IN the_DT p_NN 53_CD tumor_NN
        suppressor_NN gene_NN ._. Affected_NNP individuals_NNS develop_VBP a_DT large_JJ
        spectrum_NN of_IN CNS_NNP and_CC extra-_NN CNS_NNP neoplasms_NNS ,_, including_VBG
        medulloblastomas_NNS [_NN 2_CD ]_NN ._. Interestingly_RB ,_, alterations_NNS in_IN p_NN 53_CD
        are_VBP relatively_RB rare_JJ in_IN sporadic_JJ medulloblastomas_NNS ,_, with_IN
        mutations_NNS detected_VBD in_IN 5_CD %_NN or_CC less_JJR of_IN cases_NNS [_NN 3_CD 4_CD ]_NN ._.
        The_DT genes_NNS most_RBS commonly_RB altered_VBN in_IN medulloblastoma_NN are_VBP
        members_NNS of_IN developmental_NN signaling_VBG pathways_NNS ._. Gorlin_NNP 's_POS
        syndrome_NN results_NNS from_IN inherited_VBN mutations_NNS in_IN the_DT Hedgehog_NNP
        receptor_NN 
        PTCH_NNP that_IN constitutively_RB activate_VBP the_DT
        pathway_NN ._. Mutations_NNP in_IN the_DT Hedgehog_NNP pathway_NN members_NNS 
        PTCH_NNP ,_, 
        PTCH_NNP 2_CD ,_, 
        SUFU_NNP and_CC 
        Smo_NNP ,_, have_VBP all_DT been_VBN identified_VBN in_IN
        sporadic_JJ medulloblastomas_NNS as_IN well_RB ,_, with_IN approximately_RB 25_CD %_NN
        of_IN cases_NNS containing_VBG mutations_NNS affecting_VBG these_DT genes_NNS [_NN 5_CD 6_CD 7_CD
        8_CD 9_CD ]_NN ._. A_DT murine_NN medulloblastoma_NN model_NN was_VBD recently_RB
        developed_VBN by_IN disruption_NN of_IN the_DT 
        PTCH_NNP gene_NN ,_, with_IN medulloblastoma-like_JJ
        tumors_NNS arising_VBG in_IN 10_CD -_: 15_CD %_NN of_IN heterozygotes_NNS by_IN 9_CD months_NNS of_IN
        age_NN [_NN 10_CD 11_CD ]_NN ._. Breeding_NNP PTCH_NNP mice_NNS to_TO p_NN 53_CD knockout_NN animals_NNS
        markedly_RB increased_VBN tumor_NN incidence_NN ._. Mice_NNS heterozygous_JJ for_IN 
        PTCH_NNP and_CC lacking_VBG p_NN 53_CD all_DT developed_VBN
        medulloblastomas_NNS by_IN 3_CD months_NNS of_IN age_NN [_NN 12_CD ]_NN ._.
        Turcot_NNP 's_POS syndrome_NN is_VBZ caused_VBN by_IN germline_NN mutations_NNS in_IN the_DT
        gene_NN 
        APC_NNP ,_, a_DT member_NN of_IN the_DT Wnt_NNP signaling_VBG
        pathway_NN ._. This_DT developmentally_RB important_JJ pathway_NN contains_VBZ
        several_JJ proteins_NNS ,_, including_VBG APC_NNP ,_, Frizzled_NNP ,_, Axin_NNP and_CC GSK_NNP 3_CD ,_,
        which_WDT act_VBP in_IN concert_NN to_TO promote_VB the_DT proteosomal_NN degradation_NN
        of_IN β-catenin_JJ [_NN 13_CD 14_CD ]_NN ._. When_WRB 
        APC_NNP is_VBZ rendered_VBN inactive_JJ by_IN mutation_NN ,_,
        β-catenin_JJ levels_NNS rise_VBP and_CC the_DT protein_NN moves_NNS into_IN the_DT
        nucleus_NN where_WRB it_PRP acts_VBZ with_IN Tcf_NNP /_NN Lef_NNP cofactors_NNS to_TO regulate_VB
        transcription_NN of_IN 
        c-myc_JJ ,_, 
        cyclin_NN D_NNP and_CC other_JJ oncogenes_NNS [_NN 15_CD ]_NN ._.
        
        APC_NNP mutations_NNS have_VBP been_VBN identified_VBN in_IN
        medulloblastoma_NN cell_NN lines_NNS and_CC up_IN to_TO 4_CD %_NN of_IN sporadic_JJ
        medulloblastomas_NNS [_NN 16_CD 17_CD ]_NN ._. Furthermore_RB ,_, point_NN mutations_NNS
        or_CC small_JJ deletions_NNS in_IN β-_NN 
        catenin_NN exon_NN 3_CD have_VBP been_VBN identified_VBN
        in_IN 5_CD -_: 10_CD %_NN of_IN sporadic_JJ medulloblastomas_NNS and_CC in_IN supratentorial_NN
        primitive_JJ neuroectodermal_NN tumors_NNS (_( PNETs_NNP )_) [_NN 17_CD 18_CD 19_CD ]_NN ._.
        Finally_RB ,_, large_JJ deletions_NNS in_IN 
        AXIN_NNP were_VBD recently_RB found_VBN in_IN 12_CD %_NN of_IN
        sporadic_JJ medulloblastomas_NNS [_NN 20_CD ]_NN ._. In_IN the_DT absence_NN of_IN Wnt_NNP
        signaling_VBG β-catenin_JJ is_VBZ sequestered_VBN in_IN the_DT cytoplasm_NN ,_, and_CC
        nuclear_JJ translocation_NN of_IN β-catenin_JJ has_VBZ been_VBN used_VBN to_TO monitor_VB
        activation_NN of_IN the_DT Wnt_NNP pathway_NN in_IN a_DT number_NN of_IN different_JJ
        tumor_NN types_NNS ._. We_PRP have_VBP previously_RB shown_VBN that_IN nuclear_JJ
        β-catenin_JJ is_VBZ present_JJ in_IN 18_CD %_NN of_IN sporadic_JJ medulloblastomas_NNS [_NN
        18_CD ]_NN ._.
        The_DT greatly_RB increased_VBN incidence_NN of_IN medulloblastomas_NNS in_IN
        patients_NNS inheriting_VBG mutations_NNS in_IN the_DT 
        APC_NNP tumor_NN suppressor_NN gene_NN suggests_VBZ
        that_DT activation_NN of_IN Wnt_NNP signaling_VBG could_MD be_VB sufficient_JJ in_IN
        some_DT cases_NNS to_TO initiate_VB medulloblastoma_NN formation_NN ._. The_DT
        mitogenic_JJ role_NN played_VBN by_IN Wnts_NNP in_IN normal_JJ CNS_NNP development_NN
        also_RB supports_VBZ the_DT concept_NN that_IN the_DT pathway_NN could_MD promote_VB
        growth_NN in_IN the_DT brain_NN [_NN 21_CD 22_CD ]_NN ._. In_IN order_NN to_TO test_VB this_DT
        hypothesis_NNS we_PRP created_VBD transgenic_JJ mice_NNS in_IN which_WDT the_DT Wnt_NNP
        pathway_NN was_VBD aberrantly_RB activated_VBN in_IN the_DT CNS_NNP ._.
        In_IN order_NN to_TO avoid_VB possible_JJ 
        in_IN utero_NN lethality_NN caused_VBN by_IN excess_JJ
        pathway_NN activity_NN ,_, we_PRP used_VBD the_DT murine_NN PrP_NNP promoter_NN element_NN
        to_TO construct_VB our_PRP$ transgenic_JJ lines_NNS ._. Wnt_NNP signaling_VBG is_VBZ known_VBN
        to_TO play_VB a_DT critical_JJ role_NN in_IN the_DT development_NN of_IN the_DT brain_NN ,_,
        and_CC the_DT midbrain_NN and_CC cerebellum_NN do_VBP not_RB form_VB in_IN animals_NNS
        lacking_VBG Wnt-_NNP 1_CD [_NN 23_CD ]_NN ._. Furthermore_RB ,_, targeted_VBN disruption_NN of_IN
        the_DT 
        frizzled-_NN 4_CD gene_NN results_NNS in_IN cerebellar_NN
        abnormalities_NNS in_IN mice_NNS [_NN 24_CD ]_NN ._. Transgene_NNP expression_NN from_IN
        the_DT PrP_NNP promoter_NN is_VBZ extremely_RB low_JJ during_IN embryonic_JJ
        development_NN ,_, with_IN high-level_JJ postnatal_NN expression_NN largely_RB
        restricted_VBD to_TO neurons_NNS and_CC glia_NN of_IN the_DT CNS_NNP [_NN 25_CD ]_NN ._.
        Transgenic_NNP mice_NNS expressing_VBG either_CC wild-type_JJ or_CC mutant_JJ
        β-catenin_JJ were_VBD generated_VBN so_IN that_IN a_DT range_NN of_IN pathway_NN
        activation_NN could_MD be_VB examined_VBN ._. Mutant_NNP β-catenin_JJ was_VBD
        stabilized_VBN by_IN a_DT serine_NN to_TO phenylalanine_NN alteration_NN in_IN codon_NN
        37_CD ,_, a_DT change_NN found_VBD in_IN human_JJ tumors_NNS ._. We_PRP hypothesized_VBN that_WDT
        increased_VBN expression_NN of_IN wild-type_JJ protein_NN might_MD result_VB in_IN
        modest_JJ activation_NN of_IN the_DT pathway_NN ,_, while_IN expression_NN of_IN
        mutant_JJ ,_, stabilized_VBN protein_NN would_MD increase_VB Wnt_NNP signaling_VBG
        activity_NN more_RBR significantly_RB ._. The_DT mutant_JJ β-catenin_JJ
        accumulated_VBN in_IN neuronal_NN nuclei_NN in_IN our_PRP$ transgenic_JJ mice_NNS ,_, but_CC
        no_DT tumors_NNS or_CC other_JJ microscopic_JJ abnormalities_NNS were_VBD detected_VBN ._.
        The_DT lack_NN of_IN aberrant_NN neuronal_NN proliferation_NN in_IN our_PRP$ mice_NNS
        suggests_VBZ that_IN differentiated_JJ neurons_NNS may_MD not_RB be_VB as_IN
        susceptible_JJ to_TO the_DT mitogenic_JJ effects_NNS of_IN Wnt_NNP signaling_VBG as_IN
        are_VBP neuroepithelial_NN progenitor_NN cells_NNS [_NN 22_CD ]_NN ._.
      
      
        Methods_NNP
        
          Cell_NNP culture_NN
          Medulloblastoma_NNP DAOY_NNP cells_NNS were_VBD obtained_VBN from_IN the_DT
          American_NNP Type_NNP Culture_NNP Collection_NNP and_CC maintained_VBN in_IN
          Improved_JJ MEM_NNP Zn_NNP +_NN +_NN Option_NN (_( Richter_NNP 's_POS Modification_NNP )_) medium_NN
          containing_VBG supplemented_JJ with_IN 20_CD %_NN fetal_JJ bovine_JJ serum_NN (_( Life_NNP
          Technologies_NNPS ,_, Inc_NNP ._. ,_, USA_NNP )_) ._. The_DT TOPFLASH_NNP Wnt_NNP reporter_NN
          plasmid_NN was_VBD obtained_VBN from_IN Dr_NNP ._. Kenneth_NNP Kinzler_NNP ._. FLAG_NNP
          epitope_NN tagged_VBN wild-type_JJ and_CC S_NNP 37_CD F_NN mutant_JJ β-catenin_JJ in_IN
          pCINeo_NN expression_NN vectors_NNS were_VBD the_DT kind_NN gifts_NNS of_IN Dr_NNP ._.
          Patrice_NNP Morin_NNP [_NN 26_CD ]_NN ._. Cells_NNP were_VBD plated_JJ at_IN a_DT density_NN of_IN
          300_CD ,_, 000_CD per_IN 60_CD mm_NN plate_NN ._. Transient_NNP transfections_NNS of_IN
          β-catenin_JJ ,_, β-galactosidase_JJ and_CC Wnt_NNP reporter_NN plasmids_NNS were_VBD
          performed_VBN using_VBG the_DT Fugene_NNP reagent_NN 24_CD hours_NNS after_IN initial_JJ
          plating_VBG (_( Roche_NNP Molecular_NNP Biochemicals_NNP )_) ._. Cells_NNP were_VBD
          harvested_VBN for_IN reporter_NN assays_NNS 48_CD hours_NNS after_IN
          transfection_NN ._. All_DT experiments_NNS were_VBD performed_VBN in_IN
          quadruplicate_NN ._. β-galactosidase_JJ and_CC luciferase_NN activities_NNS
          were_VBD measured_VBN using_VBG standard_JJ techniques_NNS ._. β-galactosidase_JJ
          activity_NN was_VBD used_VBN to_TO control_VB for_IN transfection_NN
          efficiency_NN ._.
        
        
          Transgenic_NNP mice_NNS
          Transgene_NNP constructs_NNS were_VBD created_VBN using_VBG wild-type_JJ or_CC
          S_NNP 37_CD F_NN mutant_JJ β-catenin_JJ cDNAs_NNS with_IN 3_CD '_POS FLAG_NNP epitope_NN
          sequences_NNS ._. β-catenin_JJ cDNAs_NNS were_VBD inserted_VBN into_IN the_DT
          previously_RB described_VBN pBS_NN /_NN MoPrP_NNP ._. Xho_NNP vector_NN and_CC the_DT
          orientation_NN verified_VBN by_IN sequencing_VBG [_NN 25_CD ]_NN ._. The_DT resulting_VBG
          construct_VB was_VBD linearized_JJ and_CC gel-purified_JJ prior_RB to_TO
          injection_NN into_IN B_NNP 6_CD /_NN SJL_NNP mouse_NN embryos_NNS ._. Transgenic_NNP lines_NNS
          were_VBD established_VBN using_VBG standard_JJ methods_NNS at_IN the_DT Johns_NNP
          Hopkins_NNP Transgenic_NNP Core_NNP Facility_NNP ._. Human_NNP β-catenin_JJ exon_NN 3_CD
          was_VBD PCR-amplified_NNP from_IN transgenic_JJ mouse_NN DNA_NNP and_CC sequenced_JJ
          to_TO verify_VB presence_NN or_CC absence_NN of_IN the_DT codon_NN 37_CD mutations_NNS ._.
          Mice_NNS were_VBD maintained_VBN on_IN a_DT B_NNP 6_CD /_NN SJL_NNP hybrid_JJ background_NN ._.
          DNA_NNP was_VBD extracted_VBN from_IN tail_NN clips_NNS by_IN proteinase_NN K_NNP
          digestion_NN followed_VBN by_IN ethanol_NN precipitation_NN ._. The_DT
          transgene_NN was_VBD detected_VBN by_IN PCR_NNP amplification_NN of_IN a_DT 200_CD bp_NN
          product_NN using_VBG a_DT forward_JJ primer_NN located_VBN in_IN the_DT β-catenin_JJ
          cDNA_NN sequence_NN (_( βcat_NN 3_CD pb_NN :_: 5_CD '_POS TCGTTCTTTTCACTCTGGTGGAT_NNP 3_CD '_POS )_)
          and_CC a_DT reverse_JJ primer_NN in_IN the_DT PrP_NNP promoter_NN (_( PrP-S_NNP :_: 5_CD '_POS
          GTGGATACCCCCTCCCCCAGCCTAGACC_NNP 3_CD '_POS )_) ._. A_DT 750_CD bp_NN control_NN band_NN
          was_VBD produced_VBN by_IN amplification_NN from_IN the_DT endogenous_JJ PrP_NNP
          gene_NN using_VBG PrP-S_NNP and_CC the_DT reverse_JJ primer_NN (_( PrP-AS_NNP :_: 5_CD '_POS
          CCTCTTTGTGACTATGTGGACTGATGTCGG_NNP 3_CD '_POS )_) ._.
          Homozygous_NNP null_NN P_NN 53_CD knockout_NN mice_NNS (_( B_NNP 6_CD ._. 129_CD S_NNP 2_CD -_: Trp_NNP 53_CD
          tm_NN 1_CD Tyj_NNP )_) were_VBD purchased_VBN from_IN Jackson_NNP Labs_NNPS and_CC crossed_VBN with_IN
          β-catenin_JJ transgenic_JJ mice_NNS ._. Transgenic_NNP p_NN 53_CD heterozygous_JJ
          mice_NNS were_VBD then_RB crossed_VBN with_IN non-transgenic_JJ p_NN 53_CD
          heterozygotes_NNS to_TO produce_VB β-catenin_JJ transgenic_JJ ,_, p_NN 53_CD null_NN
          mice_NNS ._. p_NN 53_CD genotyping_VBG was_VBD done_VBN by_IN PCR_NNP from_IN tail_NN DNA_NNP
          according_VBG to_TO the_DT Jackson_NNP Labs_NNPS Protocol_NNP using_VBG their_PRP$
          oIMR_NN 336_CD ,_, oIMR_NN 337_CD ,_, oIMR_NN 013_CD and_CC oIMR_NN 014_CD primers_NNS ._.
        
        
          Phenotypic_NNP analysis_NN
          Mouse_NNP brains_NNS were_VBD removed_VBN immediately_RB after_IN sacrifice_NN
          and_CC fixed_VBN for_IN 24_CD -_: 48_CD hours_NNS in_IN 10_CD %_NN buffered_JJ formalin_NN ._.
          Brains_NNP were_VBD sectioned_JJ sagitally_RB or_CC coronally_RB and_CC
          haematoxylin_NN and_CC eosin_NN stained_JJ slides_NNS examined_VBN by_IN a_DT
          pathologist_NN (_( CGE_NNP or_CC DLH_NNP )_) ._. Complete_JJ necropsies_NNS were_VBD done_VBN
          on_IN mice_NNS that_WDT died_VBD unexpectedly_RB (_( DLH_NNP )_) ._.
        
        
          Western_NNP blotting_VBG
          10_CD %_NN weight_NN /_NN volume_NN protein_NN homogenates_NNS were_VBD prepared_VBN
          from_IN mouse_NN brain_NN as_RB previously_RB described_VBD [_NN 27_CD ]_NN ._. Nuclear_NNP
          and_CC cytoplasmic_JJ protein_NN fractions_NNS were_VBD prepared_VBN with_IN
          NE-PER_NNP Nuclear_NNP and_CC Cytoplasmic_NNP Extraction_NNP Reagents_NNP using_VBG
          the_DT manufacturer_NN 's_POS instructions_NNS (_( Pierce_NNP Chemical_NNP Co_NNP ._. ,_,
          Rockford_NNP ,_, IL_NNP )_) ._. HSP_NNP 90_CD ,_, a_DT cytoplasmic_JJ protein_NN ,_, was_VBD used_VBN to_TO
          control_VB for_IN loading_NN ,_, and_CC for_IN separation_NN of_IN nuclear_JJ and_CC
          cytoplasmic_JJ fractions_NNS ._.
          Samples_NNP were_VBD resolved_VBN (_( 20_CD μg_NN per_IN lane_NN total_JJ protein_NN ,_,
          12_CD ._. 5_LS μg_NN nuclear_JJ and_CC cytoplasmic_JJ fractions_NNS )_) by_IN SDS-PAGE_NNP ._.
          Primary_JJ antibody_NN incubations_NNS were_VBD carried_VBN out_IN overnight_JJ
          at_IN 4_CD °_NN C_NNP ._. The_DT transgene_NN product_NN was_VBD detected_VBN in_IN total_JJ
          protein_NN extracts_NNS using_VBG a_DT mouse_NN monoclonal_NN anti-_NN FLAG_NNP
          antibody_NN (_( Sigma-_NNP Aldrich_NNP ,_, St_NNP ._. Louis_NNP ,_, MO_NNP )_) diluted_VBN 1_CD :_: 1000_CD
          with_IN a_DT mouse_NN monoclonal_NN anti-_NN GAPDH_NNP antibody_NN (_( Research_NNP
          Diagnostics_NNPS Inc_NNP ._. ,_, Flanders_NNP ,_, NJ_NNP )_) diluted_VBN 1_CD :_: 150_CD ,_, 000_CD as_IN a_DT
          loading_NN control_NN ._. Total_JJ β-catenin_JJ was_VBD detected_VBN in_IN nuclear_JJ
          and_CC cytoplasmic_JJ fractions_NNS with_IN a_DT mouse_NN monoclonal_NN
          anti-β-catenin_JJ (_( E_NNP 5_LS )_) antibody_NN (_( Santa_NNP Cruz_NNP Biotechnology_NNP
          Inc_NNP ._. ,_, Santa_NNP Cruz_NNP ,_, CA_NNP )_) diluted_VBN 1_CD :_: 1000_CD ._. A_DT rabbit_NN polyclonal_NN
          anti-hsp_JJ 90_CD (_( H-_NNP 114_CD )_) antibody_NN (_( Santa_NNP Cruz_NNP )_) diluted_VBN 1_CD :_: 1000_CD
          was_VBD used_VBN as_IN a_DT control_NN ._. Primary_JJ antibodies_NNS were_VBD detected_VBN
          with_IN peroxidase-conjugated_JJ anti-mouse_JJ or_CC rabbit_NN IgG_NNP
          secondary_JJ antibodies_NNS (_( KPL_NNP ,_, Gaithersburg_NNP ,_, MD_NNP )_) diluted_VBN
          1_CD :_: 2000_CD ._. Western_NNP Lightning_NNP Chemiluminescence_NNP Reagent_NNP
          (_( Perkin_NNP Elmer_NNP Life_NNP Sciences_NNPS Inc_NNP ._. ,_, Boston_NNP ,_, MA_NNP )_) was_VBD applied_VBN
          and_CC the_DT signal_NN was_VBD visualized_JJ with_IN x-ray_JJ film_NN ._.
        
        
          Immunohistochemistry_NNP
          Formalin_NNP fixed_VBD ,_, paraffin_NN embedded_VBN mouse_NN brain_NN sections_NNS
          were_VBD deparaffinized_JJ and_CC antigen_NN retrieval_NN was_VBD performed_VBN
          for_IN 1_CD minute_NN in_IN a_DT pressure_NN cooker_NN with_IN antigen_NN unmasking_VBG
          solution_NN (_( Vector_NNP Laboratories_NNPS ,_, Burlingame_NNP ,_, CA_NNP )_) ._.
          Endogenous_NNP peroxidase_NN activity_NN was_VBD quenched_JJ with_IN 3_CD %_NN H_NNP 
          2_CD O_NNP 
          2_CD for_IN 5_CD minutes_NNS at_IN room_NN temperature_NN ._.
          Sections_NNP were_VBD incubated_JJ for_IN 45_CD minutes_NNS at_IN room_NN
          temperature_NN with_IN a_DT mouse_NN monoclonal_NN anti-β-catenin_JJ (_( E_NNP 5_LS )_)
          antibody_NN (_( Santa_NNP Cruz_NNP )_) diluted_VBN 1_CD :_: 200_CD ._. The_DT primary_JJ antibody_NN
          was_VBD visualized_JJ with_IN the_DT Vectastain_NNP Elite_NNP ABC_NNP mouse_NN kit_NN
          (_( Vector_NNP Labs_NNPS )_) ._.
        
      
      
        Results_NNS
        
          Transcriptional_NNP activity_NN of_IN β-catenin_JJ constructs_NNS in_IN
          medulloblastoma_NN DAOY_NNP cells_NNS
          In_IN order_NN to_TO evaluate_VB the_DT transcriptional_NN activity_NN of_IN
          FLAG_NNP epitope-tagged_JJ β-catenin_JJ in_IN a_DT medulloblastoma_NN cell_NN
          line_NN ,_, the_DT S_NNP 37_CD F_NN and_CC wild-type_JJ constructs_NNS were_VBD introduced_VBN
          into_IN DAOY_NNP cells_NNS along_IN with_IN the_DT Wnt_NNP pathway_NN TOPFLASH_NNP
          reporter_NN ._. This_DT reporter_NN plasmid_NN contains_VBZ three_CD optimal_NN
          TCF_NNP binding_JJ sites_NNS [_NN 28_CD ]_NN ._. TOPFLASH_NNP luciferase_NN activity_NN
          was_VBD activated_VBN 41_CD -_: fold_VB by_IN S_NNP 37_CD F_NN mutant_JJ β-catenin_JJ and_CC 3_CD ._. 8_CD
          fold_VB by_IN wild-type_JJ β-catenin_JJ in_IN DAOY_NNP cells_NNS (_( Fig_NNP ._. 1_LS )_) ._.
        
        
          β-catenin_JJ protein_NN expression_NN in_IN transgenic_JJ
          mice_NNS
          Five_CD transgenic_JJ lines_NNS were_VBD established_VBN ,_, two_CD expressing_VBG
          wild-type_JJ human_JJ β-catenin_JJ (_( WT-_NNP 1_CD ,_, 2_LS )_) and_CC three_CD expressing_VBG
          human_JJ β-catenin_JJ stabilized_VBN by_IN mutation_NN of_IN the_DT
          phosphorylation_NN site_NN at_IN residue_NN 37_CD (_( Mut-_NNP 1_CD ,_, 2_CD ,_, 3_LS )_) ._. Levels_NNP of_IN
          transgenic_JJ protein_NN were_VBD evaluated_VBN by_IN Western_JJ blot_NN using_VBG
          antibodies_NNS directed_VBN against_IN a_DT FLAG_NNP sequence_NN in_IN the_DT
          C-_NNP terminus_JJ of_IN the_DT transgenic_JJ protein_NN (_( Fig_NNP ._. 2_LS A_DT )_) ._.
          Transgenic_NNP protein_NN was_VBD expressed_VBN at_IN high_JJ levels_NNS in_IN the_DT
          brains_NNS of_IN WT-_NNP 1_CD ,_, Mut-_NNP 1_CD and_CC Mut-_NNP 2_CD mice_NNS and_CC at_IN lower_JJR levels_NNS
          in_IN the_DT WT-_NNP 2_CD and_CC Mut-_NNP 3_CD lines_NNS ._. Protein_NNP extracts_NNS prepared_VBN
          separately_RB from_IN the_DT cerebral_JJ cortex_NN and_CC
          cerebellum_NN /_NN brainstem_NN had_VBD similar_JJ protein_NN levels_NNS (_( data_NNS not_RB
          shown_VBN )_) ._. Attempts_NNS to_TO localize_NN expression_NN of_IN the_DT transgenic_JJ
          protein_NN immunohistochemically_RB in_IN brain_NN tissue_NN sections_NNS
          using_VBG anti-_NN FLAG_NNP antibodies_NNS were_VBD not_RB successful_JJ ._. To_TO
          evaluate_VB overall_JJ expression_NN levels_NNS of_IN β-catenin_JJ
          (_( transgenic_JJ and_CC endogenous_JJ )_) Western_JJ blots_NNS were_VBD probed_JJ
          with_IN an_DT antibody_NN that_IN binds_NNS both_DT human_NN and_CC murine_NN
          β-catenin_JJ ._. WT-_NNP 1_CD brains_NNS contained_VBD only_RB modestly_RB increased_VBN
          amounts_NNS of_IN protein_NN (_( data_NNS not_RB shown_VBN )_) ._. However_RB ,_, cerebellum_NN
          from_IN the_DT Mut-_NNP 1_CD and_CC Mut-_NNP 2_CD lines_NNS contained_VBD 50_CD -_: 100_CD %_NN more_RBR
          β-catenin_JJ protein_NN than_IN non-transgenic_JJ controls_NNS (_( Fig_NNP ._. 2_LS B_NNP )_) ._.
          Some_DT variation_NN in_IN β-catenin_JJ protein_NN level_NN was_VBD seen_VBN
          between_IN animals_NNS ,_, but_CC this_DT was_VBD not_RB related_VBN to_TO age_NN and_CC high_JJ
          expression_NN levels_NNS were_VBD seen_VBN at_IN all_DT time_NN points_NNS evaluated_VBN
          (_( 6_CD weeks_NNS to_TO 12_CD months_NNS ;_: data_NNS not_RB shown_VBN )_) ._.
        
        
          Nuclear_NNP β-catenin_JJ in_IN hippocampus_JJ ,_, cortex_NN and_CC
          cerebellum_NN of_IN transgenic_JJ mice_NNS
          To_TO determine_VB whether_IN expression_NN of_IN transgenic_JJ
          β-catenin_JJ resulted_VBD in_IN increased_VBN Wnt_NNP pathway_NN activity_NN we_PRP
          analysed_JJ the_DT subcellular_NN distribution_NN of_IN β-catenin_JJ in_IN the_DT
          brain_NN ._. Nuclear_JJ translocation_NN of_IN β-catenin_JJ is_VBZ generally_RB
          associated_VBN with_IN Wnt_NNP signaling_VBG activity_NN ._. Nuclear_JJ
          fractionation_NN was_VBD performed_VBN and_CC the_DT amount_NN of_IN total_JJ
          β-catenin_JJ in_IN the_DT cytoplasmic_JJ and_CC nuclear_JJ fractions_NNS
          assayed_JJ (_( Fig_NNP ._. 2_LS B_NNP )_) ._. Stains_NNP for_IN the_DT cytoplasmic_JJ protein_NN
          HSP_NNP 90_CD were_VBD used_VBN to_TO evaluate_VB fractionation_NN and_CC revealed_VBD
          some_DT contamination_NN of_IN the_DT nuclear_JJ fractions_NNS ._. Still_RB ,_, the_DT
          amount_NN of_IN β-catenin_JJ appeared_VBD significantly_RB increased_VBN in_IN
          the_DT nuclear_JJ fraction_NN of_IN CNS_NNP protein_NN extracts_NNS from_IN the_DT
          Mut-_NNP 1_CD transgenic_JJ line_NN ,_, and_CC somewhat_RB increased_VBN in_IN Mut-_NNP 2_CD
          nuclear_JJ fractions_NNS ._.
          We_PRP also_RB analysed_JJ β-catenin_JJ distribution_NN
          immunohistochemically_RB ._. In_IN non-transgenic_JJ mice_NNS β-catenin_JJ
          is_VBZ abundant_JJ in_IN cytoplasm_NN but_CC excluded_VBN from_IN hippocampal_NN ,_,
          cerebellar_NN or_CC cortical_JJ nuclei_NN (_( Fig_NNP ._. 3_LS A_DT ,_, 3_CD C_NNP )_) ._. In_IN contrast_NN ,_,
          several_JJ of_IN the_DT transgenic_JJ lines_NNS contained_VBD numerous_JJ
          neurons_NNS with_IN nuclear_JJ protein_NN in_IN the_DT hippocampus_JJ ,_, cerebral_JJ
          cortex_NN and_CC cerebellum_NN ._. Consistent_NNP with_IN the_DT nuclear_JJ
          fractionation_NN experiments_NNS described_VBD above_IN ,_, nuclear_JJ
          β-catenin_JJ was_VBD most_RBS prominent_JJ in_IN the_DT Mut-_NNP 1_CD animals_NNS ._. In_IN the_DT
          cerebellum_NN 20_CD -_: 40_CD %_NN of_IN the_DT granule_NN cell_NN nuclei_NN were_VBD
          positive_JJ ,_, and_CC positive_JJ nuclei_NN were_VBD also_RB found_VBN scattered_VBN
          throughout_IN the_DT molecular_JJ layer_NN (_( Fig_NNP ._. 3_LS B_NNP )_) ._. Purkinje_NNP cell_NN
          nuclei_NN were_VBD negative_JJ ._. In_IN the_DT cortex_NN ,_, nuclei_NN of_IN many_JJ small_JJ
          to_TO medium_NN sized_VBD neurons_NNS were_VBD strongly_RB positive_JJ (_( Fig_NNP ._. 3_LS D_NNP )_) ._.
          Nuclear_NNP β-catenin_JJ was_VBD only_RB rarely_RB detected_VBD in_IN glial_NN
          cells_NNS ,_, mostly_RB those_DT with_IN oligodendroglial_NN morphology_NN ._.
          Strongly_RB positive_JJ nuclei_NN were_VBD also_RB present_JJ in_IN the_DT dentate_NN
          gyrus_JJ and_CC pyramidal_NN cell_NN layer_NN of_IN the_DT hippocampus_JJ ._. Mut-_NNP 2_CD
          animals_NNS contained_VBD scattered_VBN β-catenin_JJ positive_JJ nuclei_NN in_IN
          the_DT hippocampus_JJ ,_, cortex_NN and_CC cerebellum_NN ,_, but_CC fewer_RBR than_IN
          were_VBD seen_VBN in_IN Mut-_NNP 1_CD ._. In_IN Mut-_NNP 3_CD animals_NNS 20_CD -_: 50_CD %_NN of_IN cerebellar_NN
          neurons_NNS in_IN the_DT granule_NN and_CC molecular_JJ layers_NNS contained_VBD
          nuclear_JJ β-catenin_JJ ,_, and_CC hippocampal_NN cells_NNS were_VBD
          occasionally_RB positive_JJ ,_, but_CC the_DT cortical_JJ neuronal_NN nuclei_NN
          were_VBD largely_RB negative_JJ ._. The_DT nuclei_NN of_IN hippocampal_NN ,_,
          cerebellar_NN and_CC cortical_JJ neurons_NNS in_IN WT-_NNP 1_CD and_CC WT-_NNP 2_CD mice_NNS
          were_VBD also_RB mostly_RB negative_JJ for_IN β-catenin_JJ ,_, although_IN
          occasional_JJ weakly_RB positive_JJ nuclei_NN were_VBD seen_VBN in_IN these_DT two_CD
          lines_NNS ._. No_DT nuclear_JJ staining_VBG was_VBD seen_VBN in_IN these_DT structures_NNS
          in_IN most_JJS non-transgenic_JJ animals_NNS ,_, suggesting_VBG that_IN weak_JJ
          activation_NN of_IN Wnt_NNP signaling_VBG may_MD occur_VB with_IN overexpression_NN
          of_IN wild_JJ type_NN β-catenin_JJ protein_NN ._. Nuclear_NNP β-catenin_JJ was_VBD
          detected_VBN in_IN the_DT thalami_NN and_CC other_JJ cortical_JJ deep_JJ grey_JJ
          matter_NN loci_NN in_IN both_DT transgenic_JJ and_CC non-transgenic_JJ
          animals_NNS ._.
          In_IN order_NN to_TO determine_VB if_IN Wnt_NNP signaling_VBG was_VBD aberrantly_RB
          active_JJ in_IN the_DT cerebellar_NN neuroblasts_NNS thought_VBD to_TO give_VB rise_NN
          to_TO some_DT medulloblastomas_NNS ,_, β-catenin_JJ immunostains_NNS were_VBD
          performed_VBN on_IN newborn_JJ Mut-_NNP 1_CD and_CC Mut-_NNP 2_CD animals_NNS ._. Nuclei_NNP in_IN
          the_DT proliferating_VBG external_JJ granule_NN cell_NN layer_NN of_IN P_NN 0_CD
          transgenics_NNS did_VBD not_RB contain_VB β-catenin_JJ ._. Nuclear_NNP β-catenin_JJ
          was_VBD also_RB absent_JJ from_IN the_DT ventricular_NN zone_NN cells_NNS in_IN P_NN 0_CD
          transgenic_JJ animals_NNS ._.
        
        
          Phenotypic_NNP analysis_NN
          The_DT most_RBS striking_JJ phenotype_NN was_VBD the_DT "_'' kinking_VBG "_'' of_IN tails_NNS
          seen_VBN in_IN lines_NNS Mut-_NNP 1_CD and_CC Mut-_NNP 3_CD (_( Table_NNP 1_LS )_) ._. A_DT large_JJ
          percentage_NN of_IN the_DT Mut-_NNP 3_CD animals_NNS had_VBD kinked_JJ tails_NNS ,_, while_IN
          in_IN the_DT Mut-_NNP 1_CD line_NN it_PRP was_VBD a_DT rare_JJ finding_NN ._. It_PRP is_VBZ not_RB clear_JJ
          why_WRB the_DT Mut-_NNP 3_CD line_NN ,_, which_WDT has_VBZ lower_JJR levels_NNS of_IN transgenic_JJ
          protein_NN in_IN the_DT cortex_NN ,_, was_VBD most_RBS susceptible_JJ to_TO tail_NN
          defects_NNS ._. Tail_NNP kinks_NNS ranged_VBD from_IN single_JJ ,_, acute_JJ bends_NNS to_TO
          multiple_JJ angulations_NNS resembling_VBG knots_NNS (_( Fig_NNP ._. 4_LS )_) ._. Kinked_NNP
          tails_NNS were_VBD of_IN normal_JJ length_NN or_CC slightly_RB shortened_VBN ._.
          Radiographic_NNP analysis_NN revealed_VBD vertebral_NN bodies_NNS in_IN the_DT
          kinked_JJ regions_NNS to_TO be_VB attenuated_JJ in_IN size_NN or_CC malformed_JJ ._.
          Peculiar_NNP circling_VBG or_CC "_'' waltzing_VBG "_'' behaviors_NNS were_VBD also_RB noted_VBN
          in_IN many_JJ of_IN the_DT transgenic_JJ animals_NNS ._. These_DT animals_NNS spun_VBN in_IN
          place_NN or_CC ran_VBD repetitively_RB in_IN tight_JJ circles_NNS for_IN up_IN to_TO 20_CD
          seconds_NNS at_IN a_DT time_NN ._. While_IN the_DT waltzing_VBG was_VBD most_RBS common_JJ in_IN
          mice_NNS expressing_VBG mutant_JJ β-catenin_JJ ,_, one_CD non-transgenic_JJ
          mouse_NN also_RB exhibited_VBN a_DT loose_JJ circling_VBG behavior_NN ._.
          Mice_NNS from_IN each_DT transgenic_JJ line_NN as_RB well_RB as_IN
          non-transgenic_JJ siblings_NNS were_VBD observed_VBN daily_JJ to_TO identify_VB
          any_DT animals_NNS with_IN signs_NNS of_IN tumors_NNS or_CC other_JJ neurological_JJ
          abnormalities_NNS ._. However_RB ,_, uncoordinated_JJ movements_NNS ,_,
          somnolence_NN ,_, or_CC poor_NN grooming_VBG ,_, as_IN is_VBZ seen_VBN in_IN PTCH_NNP animals_NNS
          developing_VBG tumors_NNS ,_, were_VBD never_RB observed_VBN ._. A_DT total_NN of_IN 69_CD
          mutant_JJ β-catenin_JJ and_CC 35_CD wild-type_JJ β-catenin_JJ animals_NNS were_VBD
          observed_VBN for_IN at_IN least_JJS nine_CD months_NNS before_IN being_VBG sacrificed_JJ
          (_( Table_NNP 1_LS )_) ._. Of_IN these_DT ,_, 41_CD Mut-_NNP 1_CD and_CC Mut-_NNP 2_CD animals_NNS
          expressing_VBG high_JJ levels_NNS of_IN mutant_JJ ,_, stabilized_VBD β-catenin_JJ
          were_VBD observed_VBN for_IN over_IN one_CD year_NN ,_, with_IN 12_CD animals_NNS reaching_VBG
          15_CD to_TO 17_CD months_NNS of_IN age_NN ._. Animals_NNS were_VBD sacrificed_JJ at_IN the_DT
          end_NN of_IN the_DT observation_NN period_NN and_CC their_PRP$ brains_NNS removed_VBN ,_,
          but_CC no_DT tumors_NNS or_CC other_JJ gross_JJ or_CC microscopic_JJ CNS_NNP
          abnormalities_NNS were_VBD detected_VBN ._. While_IN a_DT number_NN of_IN transgenic_JJ
          animals_NNS died_VBD in_IN the_DT first_JJ nine_CD months_NNS ,_, the_DT percentage_NN of_IN
          animals_NNS surviving_VBG was_VBD not_RB significantly_RB different_JJ between_IN
          the_DT transgenic_JJ and_CC non-transgenic_JJ groups_NNS (_( Table_NNP 1_LS )_) ._.
          Necropsies_NNP on_IN animals_NNS expiring_VBG prior_RB to_TO sacrifice_VB failed_VBD
          to_TO reveal_VB brain_NN tumors_NNS or_CC other_JJ CNS_NNP alterations_NNS ._. Several_JJ
          of_IN these_DT animals_NNS had_VBD glomerulonephritis_NNS ,_, but_CC overall_JJ the_DT
          causes_NNS of_IN death_NN were_VBD variable_JJ ,_, and_CC ,_, except_IN for_IN tail_NN
          kinking_VBG ,_, no_DT clear_JJ pattern_NN of_IN extra-_NN CNS_NNP defects_NNS emerged_VBD in_IN
          the_DT transgenic_JJ animals_NNS ._.
        
        
          No_DT increase_NN in_IN tumorigenesis_NNS in_IN p_NN 53_CD mutant_JJ animals_NNS
          expressing_VBG transgenic_JJ β-catenin_JJ
          To_TO increase_VB the_DT probability_NN of_IN brain_NN tumor_NN
          development_NN ,_, several_JJ transgenic_JJ lines_NNS (_( WT-_NNP 1_CD and_CC
          Mut-_NNP 1_CD ,_, 2_CD ,_, 3_LS )_) were_VBD crossed_VBN onto_IN a_DT p_NN 53_CD -_: deficient_NN background_NN ._.
          No_DT brain_NN tumors_NNS were_VBD identified_VBN among_IN the_DT 1_CD WT-_NNP 1_CD ,_, 1_CD
          Mut-_NNP 1_CD ,_, 10_CD Mut-_NNP 2_CD and_CC 2_CD Mut-_NNP 3_CD animals_NNS that_WDT were_VBD p_NN 53_CD null_NN ._.
          These_DT animals_NNS all_DT died_VBD within_IN 9_CD months_NNS from_IN lymphomas_NNS or_CC
          other_JJ extra-_NN CNS_NNP neoplasms_NNS known_VBN to_TO be_VB associated_VBN with_IN
          abrogation_NN of_IN p_NN 53_CD function_NN ._. Brain_NNP tumors_NNS were_VBD also_RB absent_JJ
          in_IN the_DT 10_CD WT-_NNP 1_CD ,_, 16_CD Mut-_NNP 1_CD ,_, 38_CD Mut-_NNP 2_CD and_CC 8_CD Mut-_NNP 3_CD animals_NNS
          that_WDT were_VBD mice_NNS heterozygous_JJ at_IN the_DT p_NN 53_CD locus_JJ ._. All_DT of_IN the_DT
          Mut-_NNP 1_CD and_CC Mut-_NNP 2_CD mice_NNS heterozygous_JJ for_IN p_NN 53_CD were_VBD observed_VBN
          for_IN at_IN least_JJS 9_CD months_NNS ,_, and_CC 17_CD were_VBD observed_VBN for_IN 13_CD to_TO 14_CD
          months_NNS ._.
        
      
      
        Discussion_NNP
        We_PRP have_VBP created_VBN transgenic_JJ mice_NNS expressing_VBG either_CC
        wild-type_JJ or_CC mutant_JJ human_JJ β-catenin_JJ in_IN differentiated_JJ
        neurons_NNS and_CC glia_NN of_IN the_DT CNS_NNP ._. The_DT mutant_JJ gene_NN encodes_NNS
        β-catenin_JJ protein_NN stabilized_VBN by_IN alteration_NN of_IN a_DT
        phosphorylation_NN site_NN required_VBN for_IN proteosomal_NN degradation_NN ._.
        In_IN the_DT transgenic_JJ line_NN expressing_VBG high_JJ levels_NNS of_IN human_JJ
        wild-type_JJ β-catenin_JJ ,_, significant_JJ amounts_NNS of_IN FLAG_NNP
        epitope-tagged_JJ protein_NN were_VBD detected_VBN ,_, however_RB overall_JJ
        β-catenin_JJ levels_NNS were_VBD only_RB slightly_RB increased_VBN ,_, suggesting_VBG
        the_DT mechanisms_NNS that_WDT normally_RB regulate_VB β-catenin_JJ level_NN were_VBD
        able_JJ to_TO compensate_VB for_IN the_DT addition_NN of_IN the_DT human_JJ transgenic_JJ
        protein_NN ._. In_IN contrast_NN ,_, expression_NN of_IN S_NNP 37_CD F_NN mutant_JJ β-catenin_JJ
        resulted_VBD in_IN a_DT 50_CD -_: 100_CD %_NN increase_NN in_IN overall_JJ CNS_NNP β-catenin_JJ
        protein_NN levels_NNS ._. Expression_NNP of_IN the_DT transgene_NN seemed_VBD to_TO be_VB
        higher_JJR in_IN selected_VBN neuronal_NN populations_NNS ._. β-catenin_JJ nuclear_JJ
        translocation_NN was_VBD detected_VBN in_IN a_DT subset_NN of_IN hippocampal_NN ,_,
        cortical_JJ and_CC cerebellar_NN neurons_NNS normally_RB lacking_VBG nuclear_JJ
        protein_NN ,_, consistent_JJ with_IN activation_NN of_IN the_DT canonical_JJ Wnt_NNP
        pathway_NN in_IN these_DT cells_NNS ._.
        Two_CD lines_NNS of_IN evidence_NN suggest_VBP that_IN the_DT stabilized_VBN
        β-catenin_JJ protein_NN in_IN our_PRP$ mice_NNS is_VBZ biologically_RB active_JJ and_CC
        promotes_VBZ Wnt_NNP signaling_VBG ._. First_LS ,_, co-transfection_JJ of_IN the_DT cDNA_NN
        used_VBN to_TO make_VB our_PRP$ transgenic_JJ mice_NNS and_CC the_DT TOPFLASH_NNP Wnt_NNP
        pathway_NN reporter_NN plasmid_NN into_IN DAOY_NNP medulloblastoma_NN cells_NNS
        resulted_VBD in_IN over_IN forty-fold_JJ induction_NN of_IN reporter_NN activity_NN ._.
        Similar_JJ results_NNS were_VBD reported_VBN for_IN this_DT FLAG_NNP epitope-tagged_JJ
        mutant_JJ in_IN other_JJ cell_NN lines_NNS [_NN 26_CD ]_NN ._. Second_JJ ,_, the_DT tail_NN
        kinking_VBG and_CC "_'' waltzing_VBG "_'' phenotypes_NNS in_IN our_PRP$ transgenic_JJ animals_NNS
        expressing_VBG stabilized_VBN human_JJ β-catenin_JJ are_VBP highly_RB similar_JJ to_TO
        those_DT seen_VBN in_IN 
        Fused_NNP mice_NNS [_NN 29_CD ]_NN ._. 
        Fused_NNP encodes_NNS the_DT murine_NN Axin_NNP
        homologue_NN ,_, and_CC mutation_NN of_IN this_DT gene_NN results_NNS in_IN activation_NN
        of_IN Wnt_NNP signaling_VBG [_NN 30_CD ]_NN ._. The_DT tail_NN kinking_VBG in_IN our_PRP$ animals_NNS
        presumably_RB results_VBZ from_IN low_JJ level_NN expression_NN of_IN the_DT mutant_JJ
        transgene_NN 
        in_IN utero_NN during_IN vertebral_NN patterning_VBG ._.
        The_DT circling_VBG behavior_NN could_MD be_VB due_JJ either_CC to_TO ongoing_JJ
        aberrant_NN Wnt_NNP activity_NN in_IN the_DT adult_NN brain_NN ,_, or_CC to_TO subtle_JJ
        developmental_NN defects_NNS that_WDT are_VBP not_RB easily_RB detectable_JJ
        microscopically_RB ._. We_PRP observed_VBD the_DT tail_NN and_CC behavioral_JJ
        phenotypes_NNS in_IN multiple_JJ transgenic_JJ lines_NNS ,_, suggesting_VBG they_PRP
        are_VBP not_RB caused_VBN by_IN disruption_NN of_IN an_DT endogenous_JJ gene_NN by_IN
        transgene_NN integration_NN ._.
        Our_PRP$ Western_JJ blot_NN analysis_NN showed_VBD that_IN transgenic_JJ protein_NN
        was_VBD expressed_VBN in_IN the_DT cortex_NN and_CC cerebellum_NN from_IN the_DT
        earliest_JJS time_NN point_NN assayed_JJ ,_, six_CD weeks_NNS post-gestation_JJ ,_,
        through_IN 12_CD months_NNS of_IN age_NN ._. As_IN has_VBZ been_VBN previously_RB reported_VBN ,_,
        in_IN non-transgenic_JJ animals_NNS we_PRP detected_VBD nuclear_JJ β-catenin_JJ
        only_RB in_IN the_DT thalamus_JJ and_CC other_JJ deep_JJ grey_JJ matter_NN structures_NNS
        [_NN 31_CD ]_NN ._. In_IN transgenic_JJ lines_NNS expressing_VBG mutant_JJ ,_, stabilized_VBN
        protein_NN ,_, immunohistochemical_JJ analysis_NN revealed_VBD nuclear_JJ
        β-catenin_JJ in_IN both_DT internal_JJ granule_NN layer_NN (_( IGL_NNP )_) and_CC
        molecular_JJ layer_NN neurons_NNS of_IN the_DT cerebellum_NN ._. Cortical_NNP neurons_NNS
        and_CC hippocampal_NN granule_NN and_CC pyramidal_NN cells_NNS also_RB contained_VBD
        nuclear_JJ β-catenin_JJ in_IN transgenic_JJ but_CC not_RB non-transgenic_JJ
        animals_NNS ._. We_PRP also_RB examined_VBD the_DT subcellular_NN localization_NN of_IN
        mutant_JJ β-catenin_JJ in_IN newborn_JJ transgenic_JJ mice_NNS ._. In_IN these_DT P_NN 0_CD
        animals_NNS we_PRP failed_VBD to_TO identify_VB nuclear_JJ β-catenin_JJ in_IN the_DT
        proliferative_JJ cells_NNS of_IN the_DT cerebellar_NN external_JJ granule_NN cell_NN
        layer_NN or_CC in_IN periventricular_NN neuroblasts_NNS ._. Thus_RB in_IN our_PRP$
        transgenic_JJ animals_NNS ,_, aberrant_NN Wnt_NNP activation_NN appears_VBZ to_TO be_VB
        limited_VBN to_TO mature_VB ,_, postmitotic_JJ neurons_NNS ._.
        Wnt_NNP activation_NN in_IN the_DT adult_NN hippocampus_JJ ,_, cortex_NN and_CC
        cerebellum_NN did_VBD not_RB result_VB in_IN tumors_NNS or_CC other_JJ CNS_NNP
        malformations_NNS ._. Strain_NNP effects_NNS are_VBP unlikely_JJ to_TO have_VB played_VBN a_DT
        role_NN in_IN this_DT lack_NN of_IN a_DT neoplastic_JJ phenotype_NN ,_, as_IN mice_NNS with_IN
        the_DT same_JJ background_NN as_IN the_DT one_CD we_PRP used_VBD have_VBP previously_RB been_VBN
        shown_VBN to_TO develop_VB medulloblastomas_NNS [_NN 12_CD ]_NN ._. We_PRP further_RBR
        attempted_VBD to_TO induce_VB CNS_NNP tumors_NNS by_IN abrogating_VBG p_NN 53_CD function_NN
        in_IN conjunction_NN with_IN transgenic_JJ β-catenin_JJ expression_NN ._. The_DT
        rational_JJ for_IN this_DT approach_NN was_VBD the_DT markedly_RB increased_VBN
        incidence_NN of_IN medulloblastomas_NNS seen_VBN in_IN PTCH_NNP heterozygotes_NNS
        deficient_NN for_IN p_NN 53_CD ,_, and_CC the_DT enhanced_JJ intestinal_NN adenoma_NN
        phenotype_NN of_IN 
        p_NN 53_CD null_NN ,_, APC_NNP heterozygous_JJ 
        Min_NNP mice_NNS [_NN 12_CD 32_CD ]_NN ._. We_PRP did_VBD not_RB
        observe_VB any_DT significant_JJ phenotypic_JJ changes_NNS in_IN the_DT CNS_NNP of_IN
        β-catenin_JJ transgenic_JJ animals_NNS heterozygous_JJ or_CC homozygous_JJ for_IN
        disruption_NN of_IN the_DT 
        p_NN 53_CD locus_JJ ._. However_RB ,_, most_JJS of_IN the_DT
        β-catenin_JJ transgenic_JJ mice_NNS heterozygous_JJ for_IN 
        p_NN 53_CD were_VBD followed_VBN for_IN only_RB 9_CD months_NNS ,_,
        and_CC it_PRP is_VBZ possible_JJ that_IN some_DT of_IN these_DT mice_NNS could_MD develop_VB
        tumors_NNS at_IN a_DT later_JJ age_NN ._.
        In_IN transgenic_JJ mice_NNS expressing_VBG mutant_JJ β-catenin_JJ in_IN the_DT
        breast_NN or_CC colon_NN ,_, protein_NN levels_NNS similar_JJ to_TO those_DT we_PRP
        describe_VBP are_VBP sufficient_JJ to_TO promote_VB abnormal_JJ differentiation_NN
        and_CC tumors_NNS ._. Harada_NNP and_CC colleagues_NNS documented_VBN intestinal_NN
        polyposis_NNS in_IN β-catenin_JJ transgenic_JJ mice_NNS with_IN a_DT less_JJR than_IN
        2_CD -_: fold_VB increase_NN in_IN β-catenin_JJ protein_NN level_NN in_IN the_DT polyps_NNS [_NN
        33_CD ]_NN ._. The_DT authors_NNS point_VBP out_IN that_IN because_IN the_DT transgene_NN was_VBD
        only_RB expressed_VBN in_IN a_DT fraction_NN of_IN cells_NNS in_IN this_DT tissue_NN ,_,
        protein_NN levels_NNS are_VBP likely_JJ higher_JJR in_IN some_DT epithelial_NN cells_NNS ._.
        A_DT similar_JJ explanation_NN can_MD be_VB applied_VBN to_TO our_PRP$ mice_NNS ,_, in_IN which_WDT
        nuclear_JJ translocation_NN of_IN β-catenin_JJ was_VBD only_RB detected_VBN in_IN a_DT
        fraction_NN of_IN neurons_NNS ._. A_DT 2_CD -_: fold_VB to_TO 3_CD -_: fold_VB increase_NN of_IN
        β-catenin_JJ level_NN in_IN the_DT mammary_JJ glands_NNS of_IN transgenic_JJ mice_NNS
        also_RB results_VBZ in_IN aberrant_NN differentiation_NN and_CC tumors_NNS [_NN 34_CD 35_CD
        ]_NN ._. Thus_RB while_IN it_PRP is_VBZ possible_JJ that_IN a_DT greater_JJR than_IN 2_CD -_: fold_VB
        increase_NN in_IN β-catenin_JJ level_NN would_MD have_VB a_DT neoplastic_JJ effect_NN
        on_IN adult_NN neurons_NNS ,_, evidence_NN from_IN other_JJ transgenic_JJ models_NNS
        suggests_VBZ the_DT increased_VBN protein_NN level_NN in_IN our_PRP$ mice_NNS could_MD be_VB
        sufficient_JJ for_IN tumor_NN promotion_NN ._. Overall_RB ,_, our_PRP$ data_NNS suggest_VBP
        that_DT activation_NN of_IN Wnt_NNP signaling_VBG in_IN adult_NN cerebellar_NN and_CC
        cortical_JJ neurons_NNS may_MD not_RB be_VB sufficient_JJ for_IN formation_NN of_IN
        medulloblastoma_NN /_NN PNET_NNP ._.
        Recent_JJ experiments_NNS by_IN Fults_NNP and_CC colleagues_NNS support_VBP the_DT
        idea_NN that_WDT stabilized_VBD β-catenin_JJ expression_NN in_IN the_DT postnatal_NN
        CNS_NNP is_VBZ not_RB sufficient_JJ to_TO initiate_VB tumor_NN formation_NN [_NN 36_CD ]_NN ._.
        Using_VBG the_DT RCAS-TVA_NNP system_NN they_PRP showed_VBD that_DT overexpression_NN
        of_IN c-myc_JJ ,_, but_CC not_RB of_IN activated_VBN β-catenin_JJ ,_, promoted_VBD the_DT
        proliferation_NN of_IN neural_NN progenitor_NN cells_NNS 
        in_IN vivo_NN and_CC 
        in_IN vitro_NN ._. In_IN their_PRP$ 
        in_IN vivo_NN experiments_NNS expression_NN was_VBD
        initiated_VBN in_IN nestin_NN positive_JJ cells_NNS postnatally_RB via_IN
        injection_NN of_IN β-catenin_JJ stabilized_VBN by_IN a_DT point_NN mutation_NN in_IN
        codon_NN 37_CD ._.
        Activation_NNP of_IN the_DT Wnt_NNP pathway_NN in_IN primitive_JJ
        neuroepithelial_NN cells_NNS 
        in_IN utero_NN results_NNS in_IN a_DT quite_RB different_JJ
        outcome_NN ._. Chenn_NNP and_CC Walsh_NNP recently_RB created_VBD transgenic_JJ mice_NNS
        in_IN which_WDT β-catenin_JJ stabilized_VBN by_IN an_DT amino-terminal_JJ
        truncation_NN was_VBD expressed_VBN in_IN subventricular_NN zone_NN precursor_NN
        cells_NNS 
        in_IN utero_NN under_IN control_NN of_IN the_DT nestin_NN
        promoter_NN [_NN 22_CD ]_NN ._. Brains_NNP from_IN these_DT transgenic_JJ embryos_NNS
        contained_VBD increased_VBN numbers_NNS of_IN periventricular_NN
        neuroepithelial_NN cells_NNS because_IN a_DT greater_JJR number_NN of_IN the_DT
        precursors_NNS re-entered_VBD the_DT cell_NN cycle_NN after_IN mitosis_NNS ._. The_DT
        cerebellar_NN phenotype_NN in_IN these_DT mice_NNS was_VBD not_RB reported_VBN ,_, and_CC it_PRP
        is_VBZ not_RB clear_JJ if_IN the_DT aberrantly_RB proliferating_VBG
        neuroepithelial_NN precursors_NNS in_IN their_PRP$ mice_NNS represent_VBP a_DT
        pre-neoplastic_JJ population_NN ._. These_DT transgenic_JJ lines_NNS express_VBP
        β-catenin_JJ lacking_VBG the_DT entire_JJ amino-terminal_JJ inhibitory_NN
        domain_NN ,_, and_CC this_DT truncating_VBG β-catenin_JJ mutation_NN they_PRP may_MD
        have_VB an_DT increased_VBN or_CC changed_VBN activity_NN compared_VBN to_TO our_PRP$
        construct_VB ._. Alternatively_RB ,_, the_DT contrast_NN between_IN the_DT 
        in_IN utero_NN cortical_JJ changes_NNS reported_VBN by_IN
        Chenn_NNP and_CC Walsh_NNP and_CC the_DT lack_NN of_IN a_DT CNS_NNP phenotype_NN in_IN our_PRP$ mice_NNS
        or_CC those_DT of_IN Fults_NNP could_MD indicate_VB that_IN the_DT developmental_NN
        stage_NN of_IN the_DT neuroepithelial_NN cells_NNS in_IN which_WDT stabilized_VBD
        β-catenin_JJ is_VBZ expressed_VBN is_VBZ critical_JJ ._.
        In_IN summary_NN ,_, we_PRP have_VBP expressed_VBN wild-type_JJ and_CC mutant_JJ ,_,
        stabilized_VBD human_JJ β-catenin_JJ in_IN differentiated_JJ neurons_NNS and_CC
        glia_NN of_IN adult_NN transgenic_JJ mice_NNS ._. While_IN expression_NN of_IN
        wild-type_JJ human_JJ protein_NN does_VBZ not_RB significantly_RB alter_VB
        overall_JJ β-catenin_JJ levels_NNS ,_, stabilized_VBN protein_NN accumulates_NNS in_IN
        hippocampal_NN ,_, cortical_JJ and_CC cerebellar_NN neurons_NNS and_CC
        translocates_NNS into_IN their_PRP$ nuclei_NN ._. The_DT tail_NN kinking_VBG in_IN these_DT
        mice_NNS is_VBZ highly_RB similar_JJ to_TO the_DT phenotype_NN seen_VBN in_IN Axin_NNP
        mutants_NNS with_IN activated_VBN Wnt_NNP signaling_VBG ,_, indicating_VBG the_DT
        β-catenin_JJ protein_NN expressed_VBD in_IN our_PRP$ transgenic_JJ mice_NNS is_VBZ
        functional_JJ ._. However_RB ,_, no_DT tumors_NNS ,_, pre-neoplastic_JJ changes_NNS or_CC
        other_JJ CNS_NNP morphologic_JJ alterations_NNS were_VBD detected_VBN ,_, suggesting_VBG
        that_DT postnatal_NN aberrant_NN Wnt_NNP activation_NN is_VBZ not_RB sufficient_JJ to_TO
        induce_VB CNS_NNP tumorigenesis_NNS in_IN mice_NNS ._. It_PRP is_VBZ possible_JJ ,_, however_RB ,_,
        that_IN higher_JJR β-catenin_JJ protein_NN levels_NNS ,_, or_CC expression_NN in_IN
        undifferentiated_JJ precursor_NN cells_NNS 
        in_IN utero_NN ,_, would_MD result_VB in_IN tumor_NN
        formation_NN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Authors_NNP '_'' contributions_NNS
        JEK_NNP ,_, DS_NNP ,_, HHS_NNP and_CC CGE_NNP carried_VBD out_IN molecular_JJ genetic_JJ and_CC
        immunohistochemical_JJ studies_NNS ._. JEK_NNP ,_, DLH_NNP and_CC CGE_NNP cared_VBD for_IN and_CC
        necropsied_JJ animals_NNS ._. DLP_NNP ,_, DRB_NNP and_CC CGE_NNP conceived_VBD of_IN the_DT
        study_NN ,_, and_CC participated_VBD in_IN its_PRP$ design_NN and_CC coordination_NN ._. All_DT
        authors_NNS read_VBP and_CC approved_VBD the_DT final_JJ manuscript_NN ._.
      
    
  
